|
Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
|
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen |
Speakers' Bureau - Amgen; Celgene |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Janssen; Karyopharm Therapeutics; Novartis; Takeda |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Sanofi; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen |
|
|
Honoraria - Amgen; Genesis Pharma; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Janssen-Cilag |
Research Funding - Amgen; Genesis Pharma; Karyopharm Therapeutics; Takeda |
Travel, Accommodations, Expenses - Amgen; Genesis Pharma; Takeda |
|
|
Stock and Other Ownership Interests - Kyan Therapeutics |
Honoraria - Abbvie; Amgen; Celgene; Janssen; Novartis; Takeda |
Consulting or Advisory Role - InvitroCue |
Research Funding - Celgene; Janssen |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Pierre Fabre; Roche; Sanofi; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Gilead Sciences; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Roche; Takeda |
Travel, Accommodations, Expenses - Takeda |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Janssen; Ono Pharmaceutical; Takeda |
Consulting or Advisory Role - Abbvie; GlaxoSmithKline; Janssen; Ono Pharmaceutical; Sanofi; Takeda |
Research Funding - Abbvie; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Janssen; Kiowa Kirin; Ono Pharmaceutical; Sanofi; Takeda |
|
|
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pharmamar-zeltia; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Roche |
|
|
|
Patents, Royalties, Other Intellectual Property - Takeda |
|
|
|
|
|
|
|
|
|
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Juno Therapeutics; Merck; Novartis; Takeda |
Research Funding - Bristol-Myers Squibb; Celgene; Takeda |